Glucagon-like peptide-1 vs Maridebart cafraglutide
The incretin that anchors the modern metabolic toolkit. GLP-1 agonism paired with GIP receptor antagonism — the opposite GIP direction to tirzepatide. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Glucagon-like peptide-1 GLP-1 | Maridebart cafraglutide MariTide | |
|---|---|---|
| Also known as | — | — |
| Type | Endogenous | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Proglucagon-derived peptide (~30–31 aa) | GLP-1 agonist–GIP-antagonist peptide–antibody conjugate |
| Receptor | GLP-1 receptor (GLP-1R), a class B GPCR | GLP-1 receptor (agonist) + GIP receptor (antagonist) |
| Molecular weight | ~3,297.7 Da | ≈150,000 Da |
| Half-life | ||
| Based on | Native hormone | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Glucagon-like peptide-1 and Maridebart cafraglutide?
- Glucagon-like peptide-1 is an endogenous hormone; Maridebart cafraglutide is an engineered analog based on Glucagon-like peptide-1. Glucagon-like peptide-1 signals at GLP-1 receptor (GLP-1R), a class B GPCR; Maridebart cafraglutide signals at GLP-1 receptor (agonist) + GIP receptor (antagonist).
- How do the half-lives of GLP-1 and MariTide compare?
- The reported circulating half-life of Glucagon-like peptide-1 is ~1–2 min (native; DPP-4 cleaved); Maridebart cafraglutide is ~21 days (monthly dosing). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Maridebart cafraglutide vs Glucagon-like peptide-1. Or open the interactive comparison tool to add more molecules.